Pharming (PHAR) Non-Current Debt (2019 - 2022)

Pharming (PHAR) has 4 years of Non-Current Debt data on file, last reported at $143000.0 in Q3 2022.

• Quarterly Non-Current Debt fell 62.95% year-over-year to $143000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $143000.0 (down 62.95% YoY) and the FY2021 annual result came in at $165000.0, down 22.17% from the prior year.
• Non-Current Debt slipped to $143000.0 in Q3 2022, from $152000.0 in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $19.1 million in Q4 2019 to a low of $143000.0 in Q3 2022.
• A 4-year average of $2.3 million and a median of $189000.0 in 2021 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2020 — Non-Current Debt plunged 98.92% — and 2022, when it retreated 14.29%.
• Tracing PHAR's Non-Current Debt over 4 years: stood at $19.1 million in 2019, then sank by 98.92% to $206266.1 in 2020, then dropped by 19.58% to $165875.8 in 2021, then retreated by 13.79% to $143000.0 in 2022.
• The last three Non-Current Debt figures came in at $143000.0 (Q3 2022), $152000.0 (Q2 2022), and $162000.0 (Q1 2022), per Business Quant data.